Congress has approved a sweeping bill to combat the opioid crisis. The bill addresses the problem in hundreds of ways, including requiring the U.S. Postal Service to track international packages, particularly from China, and test them for drugs. It would also make changes to Medicare and Medicaid and allow physicians’ assistants and nurse practitioners to prescribe addiction-treatment medication. (Associated Press)

A new bill would give the FDA the ability to add off-label uses to generic labels. Currently, only branded drugmakers can add off-label uses without submitting a label change, but the bill would extend that to generics, as well. (STAT)

The FDA is on track for a record low in drug marketing warning letters this year. The agency’s marketing unit has only sent four warning letters in 2018. The current record low is five, set last year. A recent peak in letters took place in 2010, when the government agency sent 51 about drug marketing and promotion. (BioPharma Dive)

Mid-stage clinical trials of a new Eli Lilly diabetes drug came back positive, putting pressure on rivals such as Novo Nordisk. The drugmaker reported its two-in-one treatment both lowered blood sugar and spurred weight loss for diabetics. Lilly is looking at the drug as both a diabetes and obesity treatment, and expects its late-stage trial to be complete in late 2021. (Reuters)

FitBit data has been used in an investigation resulting in murder charges. A woman’s wearable recorded her heart rate spiking when her alleged killer was in her home then slowing and stopping a few minutes later. Both FitBit health-monitoring and GPS data has been used to charge attackers in several cases. (New York Times)